Richard Borge, MD
Clinical Cardiac Electrophysiology · Horsham, PANPI 1205820867
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $118,500 of the $169,620 with a category attached, or 69.9%. 36 manufacturers reported payments, led by Johnson & Johnson at 34.0% of the total. Reporting peaked in 2019 at $72,343 and has fallen 97.7% since, to $1,671 in 2025. Among clinical cardiac electrophysiology clinicians in PA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 679 payments — averaging $249.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$58K
- Biotronik Inc.$35K
- Pfizer$24K
- Cardiofocus, Inc.$23K
- E.r. Squibb & Sons, L.L.C.$13K
- Boston Scientific$6K
- plus $10K from 30 others
Across 57 payments — averaging $1127.52 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Biotronik Inc.$24K
- Boston Scientific$22K
- Impulse Dynamics (USA) Inc.$10K
- Boehringer Ingelheim$8K
What the payments were for
- Consulting fees$29,86518%
- Speaking & faculty fees$118,50070%
- Travel & lodging$6,9454%
- Food & beverage$13,9748%
- Education$3370%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 103 | $57,626 |
| Biotronik Inc. | 137 | $35,302 |
| Pfizer | 54 | $23,740 |
| Cardiofocus, Inc. | 26 | $23,192 |
| E.r. Squibb & Sons, L.L.C. | 84 | $13,427 |
| Boston Scientific | 102 | $6,378 |
| Abbott | 20 | $6,161 |
| Biosense Webster, Inc. | 18 | $575 |
| Medtronic(2 entities) | 3 | $551 |
| Amgen | 25 | $446 |
| Novartis | 22 | $427 |
| AstraZeneca | 18 | $303 |
| Atricure, Inc. | 3 | $209 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 10 | $146 |
| Acutus Medical, Inc. | 3 | $134 |
| Sanofi-aventis U.S. LLC | 7 | $110 |
| Abiomed | 4 | $106 |
| Boehringer Ingelheim | 6 | $98 |
| Lexicon Pharmaceuticals, Inc. | 3 | $83 |
| Merck | 4 | $68 |
| Novo Nordisk | 3 | $60 |
| Impulse Dynamics (USA) Inc. | 1 | $56 |
| Amarin Pharma, Inc. | 4 | $52 |
| Actelion Pharmaceuticals US, Inc. | 3 | $51 |
| Lilly USA, LLC | 2 | $41 |
| Preventice Services, LLC | 1 | $37 |
| Infobionic, Inc | 1 | $36 |
| Kiniksa Pharmaceuticals, Ltd. | 2 | $30 |
| Philips North America LLC | 1 | $27 |
| Terumo Medical Corporation | 2 | $24 |
| Lundbeck LLC | 2 | $24 |
| Vital Connect, Inc | 1 | $23 |
| Endotronix, Inc. | 1 | $23 |
| GSK | 1 | $20 |
| Inspire Medical Systems, Inc. | 1 | $18 |
| Medicomp Inc | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- XARELTO$56,166
- ELIQUIS$35,248
- HeartLight System$10,331
- Edora$8,000
- Plexa$7,600
- Rivacor$7,600
- Acticor$7,600
- Sentus$7,600
- Optisure Defibrillation ICD Lead$4,966
- GENERAL BRADY$4,250
- Acticor 7 VR-T DX$925
- Edora 8 DR-T$800
- Ensite Cardiac Mapping System$624
- Watchman$412
- BioMonitor$275
- WATCHMAN Access System$269
- ENSITE$172
- Carto 3$138
- EPI-SENSE GUIDED COAGULATION SYSTEM WITH VISITRAX$115
- ATRICLIP LAA EXCLUSION SYSTEM$115
How this compares
$169,620 in reported general payments places this provider in the 90th percentile of 201 clinical cardiac electrophysiology providers in Pennsylvania.
See all clinical cardiac electrophysiology providers in Pennsylvania →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 794 | $773,548 |
| XareltoRivaroxaban | 398 | $388,993 |
| EntrestoSacubitril/Valsartan | 119 | $144,361 |
| MultaqDronedarone Hcl | 22 | $22,588 |
| Dabigatran EtexilateDabigatran Etexilate Mesylate | 51 | $15,272 |
| JardianceEmpagliflozin | 18 | $13,790 |
| Repatha SureclickEvolocumab | 25 | $13,745 |
| NexlizetBempedoic Acid/Ezetimibe | 25 | $12,800 |
| Metoprolol Succinate | 849 | $10,598 |
| Pitavastatin Calcium | 22 | $9,824 |
| Nadolol | 163 | $9,113 |
| PradaxaDabigatran Etexilate Mesylate | 16 | $7,441 |
| Flecainide Acetate | 160 | $6,882 |
| Rosuvastatin Calcium | 334 | $5,732 |
| Atorvastatin Calcium | 417 | $5,243 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $23,740 | $773,548794 claims |
| Johnson & JohnsonXarelto | $57,626 | $388,993398 claims |
| NovartisEntresto | $427 | $144,361119 claims |
| Sanofi-aventis U.S. LLCMultaq | $110 | $22,58822 claims |
| Boehringer IngelheimJardiance, Pradaxa | $98 | $21,23134 claims |
| AstraZenecaCrestor | $303 | $3,54812 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 201 clinical cardiac electrophysiology providers in Pennsylvania.
Other clinical cardiac electrophysiology in Horsham
- Seth WorleyLancaster$3.7M
- John ChenaridesPittsburgh$750K
- Fermin GarciaPhiladelphia$684K
- Ralph VerdinoPhiladelphia$682K
- Pugazhendhi VijayaramanWilkes Barre$594K
- Pasquale SantangeliPhiladelphia$581K
- Joshua SilversteinPittsburgh$557K
- Francis MarchlinskiPhiladelphia$469K
- Joshua CooperPhiladelphia$405K
- Timothy MarkmanPhiladelphia$402K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.